Bio-Rad Receives the US FDA’s Emergency Use Authorization for its Droplet Digital PCR Test Kit to Detect COVID-19

 Bio-Rad Receives the US FDA’s Emergency Use Authorization for its Droplet Digital PCR Test Kit to Detect COVID-19

Shots:

  • The US FDA has granted EUA for its COVID-19 Droplet Digital PCR (ddPCR) test that runs on Bio-Rad’s QX200 and QXDx ddPCR systems
  • Due to its high sensitivity, the test is well-suited for screening upper respiratory samples in patients with a low viral load as compared to other quantitative PCR tests. The test provides clinicians with a high degree of sensitivity to improve the accuracy of reported results
  • The EUA marks the Bio-Rad’s second EUA that has been granted for COVID-19. On Apr 30, 2020, the company has received EUA for its serology test to detect AB to the COVID-19

Click here ­to­ read full press release/ article | Ref: Bio-Rad | Image: Bio-Rad

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post